乐虎国际娛乐

English
banner
Products
Home

Nano Active Series

NANOACTIVE RESVERATROL (RES) 501-36-0

NANOACTIVE RESVERATROL (RES) 501-36-0

5% by HPLC
  • Product Details

Product Information

乐虎国际娛乐  

Product name

NanoActive Resveratrol (RES)

CAS No.

501-36-0

Quality Standard

5% by HPLC

Appearance

 Yellow, viscous and transparent liquid

Solubility

Soluble in water and oil, heated to over 40, dissolution-rate will be accelerated

 

COA of NanoActive Resveratrol (RES)

 

ITEMS

STANDARDS

RESULTS

Characteristics

Light yellow, viscous liquid

conform

Diluted in water (1: 50)

Colorless or light yellow and transparent solution

conform

Odor

Characteristic Smell

conform

Assay (HPLC)

≥5.0%

5.10%

pH (in 1:50 aqueous solution)

5.0-8.0

6.8

Density (20ºC)

1.0 – 1.1 g/cm3

conform

Heavy Metal

≤10ppm

conform

Solubility

Soluble in water and oil, heated to over 40 ℃,

conform

dissolution rate will be accelerated

Total aerobic bacteria

< 10 CFU/g

conform

Molds and Yeasts

< 10 CFU/g

conform

pathogenic bacteria

negtive

conform

Conclusion:  Conformed to specification.

乐虎国际娛乐  

Usage

乐虎国际娛乐  

Resveratrol (Res) is a non-flavonoid polyphenol compound. Resveratrol has a wide range of anti-cancer, anti-oxidation, antibacterial, anti-inflammatory activities. It can be widely used in medicine, health care products, food, cosmetics and other fields. Resveratrol highly works on many targets on the skin. As a new high- efficiency natural active substance, it can achieve good whitening, anti-wrinkle, anti-inflammation, antibacterial, acne treatment and anti-aging functions in skin care products. But disadvantages of resveratrol which is hard to dissolve in water, easily oxygenated and easy discoloration limit its application in cosmetics.

NanoActive Res乐虎国际娛乐, with a particle size of less than 30nm developed by the nano-delivery system (NSD),  completely solve the problems of dissolution of Resveratrol. Resveratrol that stably wrapped in nano-carriers can greatly increase the absorption efficiency and bioavailability.

resveratrol inhibits melanin synthesis by multiple targets



Product Efficacy of NanoActive Res

1. NanoActive Res can promote collagen synthesis, increase skin thickness and elasticity, remove wrinkles and tighten skin.
2. NanoActive Res inhibits melanin synthesis, reduces pigmentation and whitens skin
3. Remove free radicals to fight oxidation and anti-skin aging
4. NanoActive Res Promotes wound healing and reduces scarring
5. Cure acne and reduce acne pit
6. Antibacterial, anti-inflammatory, anti - sensitive and analgesia;

7. Prevent scarring and fibrosis




乐虎国际娛乐 low concentration of resveratrol (0.001%) reduced the melanin content of b16f10 cells by 50%



resveratrol has an obvious anti-wrinkle effect


Recommended Quantity: 1-5%. The optimal pH range of the system is 3.0-6.5. The finished product should avoid direct sunlight (using opaque packaging). It is recommended to add UV absorbent to daycare products
Product storage: avoid light preservation under 25 ℃

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

ECHINACEA PURPUREA EXTRACT Supplier -Sinoway
ECHINACEA PURPUREA EXTRACT
Phenols ≥ 4% , USP42
rhEGF
EPIDERMAL GROWTH FACTOR (rhEGF) 62253-63-8
less than 1EU/μg, 1.0x107 IU/mg up
ALPHA GPC
ALPHA GPC 28319-77-9
99% up, Food Grade
CEFTIOFUR SODIUM
CEFTIOFUR SODIUM 104010-37-9
In-house Specification
COPPER PEPTIDE
COPPER PEPTIDE 49557-75-7
98% up by HPLC
LIRAGLUTIDE
LIRAGLUTIDE 204656-20-2
Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage  2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: ·         Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. ·         Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). ·         Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. ·         Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

home

products

about

contact

乐优彩票登入,备用,官方网址 乐优彩票天天红单下载 乐优彩票网址是多少 乐优炫彩app 乐优炫彩app下载 乐博彩票官方app 乐优炫彩官网 乐优炫彩彩票app下载 乐体育app下载 乐善彩票网址